Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Three-Arm, Double-blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Subjects Wtih Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Brief Summary: The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.


Options:
A: Arm Label: Ertuglifozin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ertugliflozin 5 mg, Drug: Placebo to Ertugliflozin, Other: Glimepiride, Drug: Placebo to Glimepiride, Biological: Basal Insulin, Drug: Metformin | Arm Label: Ertugliflozin 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Ertugliflozin 15 mg, Other: Glimepiride, Drug: Placebo to Glimepiride, Biological: Basal Insulin, Drug: Metformin | Arm Label: Placebo/Glimepiride; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Ertugliflozin, Other: Glimepiride, Biological: Basal Insulin, Drug: Metformin | Intervention Type: DRUG; Name: Ertugliflozin 5 mg; Assigned to Arm(s): Ertuglifozin 5 mg | Intervention Type: DRUG; Name: Ertugliflozin 15 mg; Assigned to Arm(s): Ertugliflozin 15 mg | Intervention Type: DRUG; Name: Placebo to Ertugliflozin; Assigned to Arm(s): Ertuglifozin 5 mg, Placebo/Glimepiride | Intervention Type: OTHER; Name: Glimepiride; Assigned to Arm(s): Ertugliflozin 15 mg, Ertuglifozin 5 mg, Placebo/Glimepiride | Intervention Type: DRUG; Name: Placebo to Glimepiride; Assigned to Arm(s): Ertugliflozin 15 mg, Ertuglifozin 5 mg | Intervention Type: BIOLOGICAL; Name: Basal Insulin; Assigned to Arm(s): Ertugliflozin 15 mg, Ertuglifozin 5 mg, Placebo/Glimepiride | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Ertugliflozin 15 mg, Ertuglifozin 5 mg, Placebo/Glimepiride
B: Arm Label: rosiglitazone in addition to background metformin; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Metformin | Arm Label: rosiglitazone in addition to background sulfonylurea; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Sulfonylurea | Arm Label: Sulfonylurea in addition to background metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Arm Label: Metformin in addition to background sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): rosiglitazone in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background metformin
C: Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300 mg, Drug: Metformin, Drug: Sulphonylurea | Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin 100 mg, Drug: Metformin, Drug: Sulphonylurea | Intervention Type: DRUG; Name: Sitagliptin 100 mg; Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Canagliflozin 300 mg; Assigned to Arm(s): Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 300 mg, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Sulphonylurea; Assigned to Arm(s): Canagliflozin 300 mg, Sitagliptin 100 mg
D: Intervention Type: DRUG; Name: muraglitazar; Assigned to Arm(s): N/A

Answer: D